

February 15, 2025

To,
The Chief General Manager
Listing Operation,
BSE Limited,
20th Floor, P. J. Towers,
Dalal Street,
Mumbai – 400 001.
Scrip Code: 524743

Dear Sir/ Madam,

Sub: : Intimation under Regulation 30- Incorporation of Subsidiary Company

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the subsidiary of the Company in the name of "Nanyang Biologics (India) Private Limited" has been incorporated on 14th February, 2025.

The details as required under SEBI Listing Regulations, 2015 read with SEBI Circular No. CIR / CFD / CMD / 4/2015 dated 9th September 2015 are given in **Annexure A**.

This is for the information of the exchange and the members.

Thanking you,

Yours Truly,

For **FISCHER MEDICAL VENTURES LIMITED**

(Formerly known as Fischer Chemic Limited)



ARAVINDKUMAR V

COMPANY SECRETARY & COMPLAINEE OFFICER

ANNEXURE A

Sr. no.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	Nanyang Biologics (India) Private Limited Turnover: Not applicable since this is newly incorporated Company.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length".	Nanyang Biologics (India) Private Limited is a subsidiary of the Company. Accordingly, Nanyang Biologics (India) Private Limited Health Innovations Private Limited is a related party
3	Industry to which the entity being acquired belongs	Business of manufacturing, formulating, importing, exporting, distributing, marketing, processing, and packaging of nutraceuticals, dietary supplements, functional foods, herbal supplements and other health-related products for the promotion of human health
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Not Applicable.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	Not Applicable.
6	Indicative time period for completion of the acquisition.	Not Applicable.
7	Nature of consideration - whether cash consideration or share swap and details of the same.	Cash.
8	Cost of acquisition or the price at which the shares are acquired.	Rs. 51,000/- as Share Capital contribution.

Sr. no.	Particulars	Details
9	Percentage of shareholding/ control acquired and/ or number of shares acquired.	The Company owns 51% of the shareholding in the new entity viz. Nanyang Biologics (India) Private Limited.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	Not Applicable, since it's a newly incorporated company.

